- Home
- SKIN
as 03-28-2025 4:00pm EST
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | LONG BEACH |
| Market Cap: | 164.1M | IPO Year: | N/A |
| Target Price: | $2.50 | AVG Volume (30 days): | 809.2K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $4.48 | Next Earning Date: | 03-12-2025 |
| Revenue: | $334,294,000 | Revenue Growth: | -16.00% |
| Revenue Growth (this year): | 1.93% | Revenue Growth (next year): | 12.41% |
Latest The Beauty Health Company News
SKIN Breaking Stock News: Dive into SKIN Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Undervalued Penny Stocks To Watch In March 2025
GuruFocus.com
16 days ago
The Beauty Health Co (SKIN) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
GlobeNewswire
17 days ago
BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results
GlobeNewswire
25 days ago
BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
Business Wire
3 months ago
BeautyHealth Appoints Stephen J. Fanning to Board of Directors
Business Wire
4 months ago
BeautyHealth Releases 2024 Skintuition Report
Simply Wall St.
4 months ago
Beauty Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
5 months ago
The Beauty Health Co (SKIN) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...
Compare SKIN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKIN The Beauty Health Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.